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Abstract
Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-
cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for
bronchodilatory, immunomodulatory and mucus secretion modulating effects by interacting with the VIP receptors
VPAC1 and VPAC2, it is discussed to be a promising target for pharmaceutical intervention in common diseases
such as COPD and bronchial asthma. Here we examined the expression and transcriptional regulation of VPAC1 in
the lungs of allergic mice using an ovalbumin (OVA) -induced model of allergic asthma. Mice were sensitized to
OVA and challenged with an OVA aerosol. In parallel a control group was sham sensitized with saline. VPAC1
expression was examined using RT-PCR and real time-PCR studies were performed to quantify gene transcription.
VPAC1 mRNA expression was detected in all samples of OVA-sensitized and challenged animals and control tissues.
Further realtime analysis did not show significant differences at the transcriptional level.
Although the present studies did not indicate a major transcriptional regulation of VPAC1 in states of allergic airway
inflammation, immunomodulatory effects of VPAC1 might still be present due to regulations at the translational level.
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Introduction
Respiratory diseases constitute a major part of occupational
diseases. Next to asbestosis [1,2] and tuberculosis [3,4],
bronchial asthma belongs to leading causes of the global
burden of occupational lung disease [5-7] and further in-
sights into the underlying mechanisms of the disease are
needed. Among these mechanisms, pathways of the neuro-
immune axis may play a key role. In this respect, vasoactive
intestinal peptide (VIP) is a putative neurotransmitter of
t h en o n - a d r e n e r g i cn o n - c h o l i n e r g i cn e r v o u ss y s t e mi nt h e
respiratory tract [8]. VIP-immunoreactivity is present in
cells of the tracheobronchial smooth muscle layer, in the
walls of pulmonary and bronchial vessels, around submuco-
sal glands, in the lamina propria and in pulmonary ganglia
[8,9]. VIP immuno reactive nerve fibres are found as
branching networks in the respiratory tract [8] and they are
decreasing in frequency as the airways become smaller, but
extend to peripheral bronchiols [10,11]. VIPergic nerves are
colocalized with cholinergic nerves and VIP immunoreac-
tivity is also present in sensory nerves [8,12].
VIP is a highly abundent and pleiotrophic mediator,
known for various effects, including bronchodilatation,
modulation of mucus secretion and immunomodulation.
VIP is therefore a promising target for future therapy in
chronic inflammatory lung diseases [13].
VIP binds predominantly to the two VIP-receptors
VPAC1 and VPAC2. Antiinflammatory effects have been
demonstrated to be mediated by the VPAC1 receptor
in vivo and in vitro. VPAC1 activation was shown to in-
hibit the release of inflammatory mediators from macro-
phages like IL-6, TNF-alpha, IL-12 and NO and increase
of IL-10 in a murine model of septic shock. In contrast
to VPAC2, VPAC1 also inhibits the proliferation of acti-
vated T cells and the expression of costimulatory mole-
cules like B7.1 and B7.2 [14]. A reduction of VPAC1
expression could be shown for T cells in case of activa-
tion [15].
Since VPAC1 was suggested to play the major role in the
antiinflammatory action of VIP [16] and anti-inflammatory
effects were recently described for the receptor PAC1, the
present study assessed the expression and regulation of the
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transcriptional level.
Material and methods
Asthma Model and preparation of lung tissue samples
Female BALB/c mice were sensitized to ovalbumin
(OVA) as previously described [17] by administration of
10 μg OVA and 1,5 mg Alum (Pierce, Rockford, USA) in
50 μL saline by intraperitoneal injection on days 0, 14
and 21 (n= 16) (Figure 1). The allergic response in the
respiratory tract was induced by the exposition of mice
to 1% OVA aerosol for 20 min on days 27 and 28.
24 hours after the last challenge the mice were sacrificed
by an overdose of Narcoren, (Merial, Hallbergmoos,
Germany). Lungs were then removed. The upper right
lobe was dissected and snap frozen in liquid nitrogen.
The samples were stored at −80°C until further analysis.
The animal study was performed according to inter-
nationally recognized guidelines and approved by the
local authorities (Hannover).
Generation of cDNA
As previously described [17], the lung samples were ho-
mogenized using fastprep (Bio101, Carlsbad, USA) and
total RNA was isolated using the RNeasy mini kit (Qiagen,
Hilden, Germany) according to the customer’s manual.
Quantity of RNA was controlled photometrically by OD
260/280 nm.
900 ng RNA were transcribed into cDNA using the
omniscript RT-PCR kit (Qiagen, Hilden, Germany).
RNA was denatured at 65°C for 5 minutes. After cooling
to room temperature, buffer RT, random primers, RNase
inhibitor, and omniscript for the RT-PCR were added.
The RNA was transcribed at 37°C for 90 min and the re-
action was stopped by heating up to 95°C for 5 min.
Each RNA sample was used for two approaches: First
for the RT-PCR and in a second approach as a RNA
control for genomic DNA contamination in which sam-
ples were treated like the RT-PCR samples but without
the transcriptase. Both, the cDNA and the RNA control
were immediately used for the real time-PCR.
Quantitative real time PCR
The relative amounts of cDNA were quantified using the
Light Cycler Fast Start SYBR Green Kit (Roche, Mann-
heim, Germany) according to the customer’sp r o t o c o l .
Porphobilinogen deaminase (PBGD) was used as a house
keeping gene. The DNA was amplified using the following
conditions: 10 in 95°C; 45 cycles 1 s 95°C, 10 s 68°C, 9 s
72°C. The pureness of the products was verified via a
melting curve. The products were visualized via gel
electrophoresis.
All primers were produced by MWG (Ebersberg,
Germany) and designed intron spanning to exclude the
amplification of genomic DNA in case of contamina-
tions. The PCR products were verified by DNA agarose
gel and by sequencing by the company GATC biotech
(Koblenz, Germany). The primer sequences are shown
in Table 1.
Results and discussion
Specific PCR products for VPAC1 and PBGD were
found in the lungs of both, the OVA sensitized and the
saline sensitized control group. The products were iden-
tified to be specific by gel electrophoresis (Figure 2) and
by melting curve analysis (data not shown).
To assess quantitative changes of VPAC1 mRNA ex-
pression, the VPAC1 fluorescence signal was normalized
to the house keeping gene PBGD using the program rel
quant (Roche) and displayed as relative unit. Though the
real time PCR results tend to show a slight increase of
VPAC1 expression in the lungs of OVA sensitized ani-
mals compared to the sham sensitized group (Figure 3),
no significant difference can be detected using statistical
approaches.
Although a clear alteration in the VPAC 1 expression
on RNA level could not be detected in the present study,
differential VPAC1 expression in terms of inflammatory
mechanisms had been shown before. In this respect, in
an in vitro model with different subsets of T cell subsets
the VPAC1 expression was linked to an inhibition of
proliferation and the expression of costimulatory mole-
cules [14]. VPAC1 was also shown to be downregulated
in case of activation of T cells [15].
Figure 1 Treatment protocol for the murine asthma model; OVA sensitization via i.p administration of 10 mg OVA on days 0, 14 and
21 followed by aerosolic challenges with an 1% OVA aerosol for 20 min on days 27 and 28; sacrifice on day 29.
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immune system like T cells and B cells in other compart-
ments of the body such as the intestinal system [18].
Also the infiltration of these VPAC1-positive cells during
an inflammation like in ulcerative colitis and crohn’s dis-
ease was shown to increase the amount of VPAC1 posi-
tive cells in the inflammed tissue [18].
According to literature it could be hypothesized, that
VPAC1 might play a role in the pathogenesis of bron-
chial asthma, for effects mediated by VPAC1 are present
in allergic diseases such as asthma or atopic dermatitis.
Nevertheless we did not find a regulation of VPAC1 on
the transcriptional level so far. Therefore, it is necessary
to take a more detailed look into the lung tissue on the
single cellular level and VPAC1 positive cells and the ex-
pression of VPAC1 should be quantified for each cell
population separately. Overlaps of alterations in VPAC1
expression in specific cell populations by the influx of
VPAC1 positive cells could thereby avoided. Also, regu-
lation may take place at the level of translation and fu-
ture studies should access this aspect.
Interestingly, the VPAC1 related receptor PAC1 was
recently shown to be differentially expressed in a murine
model of ovalbumin-induced asthma [17]. In this study
an increased PAC1R mRNA expression was present in
lung tissue under allergic conditions. In the state of an
asthmatic reaction, PAC1R-deficient mice (PAC1R(−/−))
and to BALB/c mice treated with the specific PAC1R
agonist maxadilan, PAC1R deficiency resulted in in-
creased inflammatory effects, while agonistic stimulation
of It was therefore concluded that anti-inflammatory ef-
fects can be achieved via PAC1 receptor and that
PAC1receptor agonists may represent a promising target
for an anti-inflammatory therapy.
In summary, the present analysed the expression and
transcriptional regulation of VPAC1 in a murine model
of allergic asthma using an established ovalbumin proto-
col. While VPAC1 mRNA expression was detected in all
samples realtime analysis did not show significant differ-
ences at the transcriptional level. Therefore further stud-
ies should quantify VPAC1 expression on the level of
single respiratory cells using modern tools of biochemis-
try [19], molecular biology [20], cell biology [21][22] and
morphology [23].
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Table 1 Primer sequences
Gene Primer forward Primer reverse Product
size
PBGD cacgatcctgaaactctgct agatggtccagaagatgaccc 224
PAC1 ttcactactgcgtggtgtccaact atatcccagcatcccgcatcatca 228
Figure 2 VPAC1 gel electrophoresis; L= 100 bp DNA ladder;
arrows point at 200 bp band; slot 1=OVA sensitized (OVs)
PBGD; slot 2= OVs VPAC1; slot 3= sham sensitized (SHs) PBGD;
slot 4=SHs VPAC1; slot 5=OVs PBGD RNA control (RC); slot 6=
OVs VPAC1 RC; slot 7=SHs PBGD RC; slot 8=SHs VPAC1 RC;
expected products: PBGD=224 bp; VPAC1=228 bp.
Figure 3 Normalized ratio of VPAC1 expression in lung tissue;
VPAC1 fluorescence signal normalized to PBGD; OVs = OVA
sensitized and challenged group, SHs = sham sensitized group.
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